Clinical Trials Logo

Osteoporosis clinical trials

View clinical trials related to Osteoporosis.

Filter by:

NCT ID: NCT03197623 Completed - Osteoporosis Clinical Trials

Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids

Start date: October 14, 2016
Phase: Phase 1
Study type: Interventional

A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women with Osteopenia Secondary to Corticosteroids

NCT ID: NCT03175874 Completed - Osteoporosis Clinical Trials

Autophagy and Pathological Aging

AVP
Start date: December 20, 2017
Phase: N/A
Study type: Interventional

Autophagy is recognized as a central mechanism for the regulation of aging. . Osteoporosis (OA) and Alzheimer's disease (AD) are two forms of pathological aging, sometimes entangled, including an over-risk of OP in AD and degradation of cognitive functions after OP fracture, but the link between These two pathologies remain poorly understood. The aim of this prospective pilot study is to evaluate the level of autophagy of osteocytes (OST) in postmenopausal women with OP and to explore the hypothesis that the defect of autophagy is one of the physiopathological links of the OP During the MA

NCT ID: NCT03164928 Completed - Clinical trials for Glucocorticoid-induced Osteoporosis

Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

Start date: May 7, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the effect of denosumab on lumbar spine bone mineral density (BMD) Z-score as assessed by dual-energy X-ray absorptiometry (DXA) at 12 months in children 5 to 17 year of age with Glucocorticoid (GC)-induced osteoporosis (GiOP).

NCT ID: NCT03127293 Completed - Clinical trials for Hyperemesis Gravidarum

Hyperemesis Gravidarum and Osteoporosis

Start date: January 1, 2015
Phase: N/A
Study type: Observational

Hyperemesis Gravidarum (HG) is a common disorder for hospitalization in the first trimester of pregnancy and related to protracted vomiting and nausea. It can be accompanied by ketonuria, dehydration and weight loss. Our aim was to investigate osteoporosis in patients with HG. In our study, we investigated osteoporosis in a total of 79 patients (40 HG and 39 control) by means of dual energy x-ray absorptiometry (DEXA) measurements and laboratory parameters related to HG.

NCT ID: NCT03125590 Completed - Osteopenia Clinical Trials

Validation, Reliability and Pilot Test of the Personalized Exercise Questionnaire (PEQ)

Start date: April 1, 2017
Phase: N/A
Study type: Observational

The PEQ is the first tool to measure facilitators, barriers, and preferences to exercise in people with osteoporosis.

NCT ID: NCT03091088 Completed - Physical Activity Clinical Trials

Effects of Physical Exercise to Prevent Osteoporosis in Postmenopausal Women

Osteo_women
Start date: February 1, 2011
Phase: N/A
Study type: Interventional

According to the World Health Organization criteria, osteoporosis was defined as a bone mineral density that lies 2.5 standard deviations or more below the average value for young healthy women. Osteoporosis is a major cause of fractures and can lead to serious complications in postmenopausal women. For this reason, approaches to prevent the appearance and progression of osteoporosis are of primary importance. This randomized clinical trial analyzes the effects of two types of physical exercise oriented to prevent osteoporosis in postmenopausal women with pharmacological supplements of Calcium and Vitamin-D.

NCT ID: NCT03087851 Completed - Osteoporosis Clinical Trials

Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis

ZOLARMAB
Start date: March 13, 2017
Phase: Phase 4
Study type: Interventional

Denosumab is an antibody against receptor-activator of nuclear factor kappa-B ligand that prevents recruitment and differentiation of mature osteoclasts. Treatment markedly decrease bone resorption and fracture risk, and many patients will reach osteopenic bone mineral density (BMD) levels on treatment with denosumab. The treatment effect on bone turnover and BMD has, however, been demonstrated to be reversible. This study will show if the bone mass can be maintained by administrating zoledronic acid and if timing of the first dose of zoledronic acid after last dose of denosumab matters.

NCT ID: NCT03051620 Completed - Osteoporosis Clinical Trials

Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate

PROSA
Start date: February 1, 2017
Phase:
Study type: Observational

The study is a cohort study comprising 136 patients with osteoporosis stopping treatment with alendronate. The study will contribute with new knowledge about biochemical markers of bone turnover as predictors of bone loss after stopping treatment with alendronate.

NCT ID: NCT03026660 Completed - Clinical trials for Postmenopausal Osteoporosis

Moringa Oleifera on Bone Density

Start date: July 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of Moringa Oleifera on the structure and function of bone in post-menopausal women ingesting 1000 mg of Moringa Oleifera daily for 12 weeks.

NCT ID: NCT03005678 Completed - Osteoporosis Clinical Trials

Denosumab Versus Bisphosphonates (Alendronate) in GIOP

Start date: April 1, 2017
Phase: Phase 4
Study type: Interventional

A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis